Lead Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Age

22 - No limit years

Sex

ALL

Healthy Volunteers

No

•The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
•The participant is ≥22 years of age on the day of signing informed consent.
•The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
•The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
•The participant with multiple nodules has one nodule that meets the criteria.
•The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.

•Patients receiving therapy for concurrent active malignancy
•Patients with a history of cardiac arrhythmias and/or pacemaker use
•Patients with lung nodules \<1cm
•Patients with lung nodules that are pure ground glass opacities (GGOs) of any size
•Patients with lung nodules that are \<50% solid of any size

Related studies

NCT06441357 · Adenocarcinoma of Lung

NCT05550961 · NSCLC, Cancer, and more

NCT05566223 · Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, and more

NCT05194735 · Gynecologic Cancer, Colorectal Cancer, and more

NCT03184571 · Lung Cancer Metastatic, NSCLC Stage IV, and more

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma